These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 29223590)

  • 1. Recent encounters with atropisomerism in drug discovery.
    Glunz PW
    Bioorg Med Chem Lett; 2018 Jan; 28(2):53-60. PubMed ID: 29223590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atropisomerism in Drug Discovery: A Medicinal Chemistry Perspective Inspired by Atropisomeric Class I PI3K Inhibitors.
    Perreault S; Chandrasekhar J; Patel L
    Acc Chem Res; 2022 Sep; 55(18):2581-2593. PubMed ID: 36069734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent progress toward developing axial chirality bioactive compounds.
    Wang Z; Meng L; Liu X; Zhang L; Yu Z; Wu G
    Eur J Med Chem; 2022 Dec; 243():114700. PubMed ID: 36058089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioactive atropisomers: Unraveling design strategies and synthetic routes for drug discovery.
    Liu SJ; Zhao Q; Liu XC; Gamble AB; Huang W; Yang QQ; Han B
    Med Res Rev; 2024 Sep; 44(5):1971-2014. PubMed ID: 38515232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atropisomerism in the Pharmaceutically Relevant Realm.
    Basilaia M; Chen MH; Secka J; Gustafson JL
    Acc Chem Res; 2022 Oct; 55(20):2904-2919. PubMed ID: 36153960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atropisomerism in medicinal chemistry: challenges and opportunities.
    Toenjes ST; Gustafson JL
    Future Med Chem; 2018 Feb; 10(4):409-422. PubMed ID: 29380622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of chromatographic and chiroptical spectroscopic techniques and methodologies in support of drug discovery for atropisomeric drug inhibitors of Bruton's tyrosine kinase.
    Dai J; Wang C; Traeger SC; Discenza L; Obermeier MT; Tymiak AA; Zhang Y
    J Chromatogr A; 2017 Mar; 1487():116-128. PubMed ID: 28131592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revealing atropisomer axial chirality in drug discovery.
    LaPlante SR; Edwards PJ; Fader LD; Jakalian A; Hucke O
    ChemMedChem; 2011 Mar; 6(3):505-13. PubMed ID: 21360821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approaches to Synthesis and Isolation of Enantiomerically Pure Biologically Active Atropisomers.
    Carlsson AC; Karlsson S; Munday RH; Tatton MR
    Acc Chem Res; 2022 Oct; 55(20):2938-2948. PubMed ID: 36194144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addressing Atropisomerism in the Development of Sotorasib, a Covalent Inhibitor of KRAS G12C: Structural, Analytical, and Synthetic Considerations.
    Lanman BA; Parsons AT; Zech SG
    Acc Chem Res; 2022 Oct; 55(20):2892-2903. PubMed ID: 36178208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atropisomerism transforming anti-cancer drug discovery.
    Patel S; Sandha K; Waingankar A; Jain P; Abhyankar A
    Chem Biol Drug Des; 2023 Jan; 101(1):138-157. PubMed ID: 36254625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A nonneglectable stereochemical factor in drug development: Atropisomerism.
    Yang YD; Yang BB; Li L
    Chirality; 2022 Oct; 34(10):1355-1370. PubMed ID: 35904531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Properties of Configurationally Stable Atropoenantiomers in Macrocyclic Natural Products and the Chrysophaentin Family.
    Bewley CA; Sulikowski GA; Yang ZJ; Bifulco G; Cho HM; Fullenkamp CR
    Acc Chem Res; 2023 Feb; 56(4):414-424. PubMed ID: 36731116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent trends and applications in liquid-phase chromatography enantioseparation of atropisomers.
    Peluso P; Mamane V; Aubert E; Cossu S
    Electrophoresis; 2017 Aug; 38(15):1830-1850. PubMed ID: 28168709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Separation of Bruton's tyrosine kinase inhibitor atropisomers by supercritical fluid chromatography.
    Yip SH; Wu DR; Li P; Sun D; Watterson SH; Zhao R; Tino J; Mathur A
    J Chromatogr A; 2019 Feb; 1586():106-115. PubMed ID: 30578026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leveraging conformational control about a potential atropisomeric axis as a strategy in medical chemistry.
    Toenjes ST; Basilaia M; Gustafson JL
    Future Med Chem; 2021 Mar; 13(5):443-446. PubMed ID: 33472413
    [No Abstract]   [Full Text] [Related]  

  • 17. Aryne Atropisomers: Chiral Arynes for the Enantiospecific Synthesis of Atropisomers and Nanographene Atropisomers.
    Coquerel Y
    Acc Chem Res; 2023 Jan; 56(2):86-94. PubMed ID: 36595619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catalytic Asymmetric Synthesis of Atropisomers Bearing Multiple Chiral Elements: An Emerging Field.
    Zhang HH; Li TZ; Liu SJ; Shi F
    Angew Chem Int Ed Engl; 2024 Jan; 63(3):e202311053. PubMed ID: 37917574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromatographic resolution of atropisomers for toxicity and biotransformation studies in pharmaceutical research.
    Yan TQ; Riley F; Philippe L; Davoren J; Cox L; Orozco C; Rai B; Hardink M
    J Chromatogr A; 2015 Jun; 1398():108-20. PubMed ID: 25937130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptoid atropisomers.
    Paul B; Butterfoss GL; Boswell MG; Renfrew PD; Yeung FG; Shah NH; Wolf C; Bonneau R; Kirshenbaum K
    J Am Chem Soc; 2011 Jul; 133(28):10910-9. PubMed ID: 21634437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.